Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: Study protocol for a randomized controlled trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Poh, Catherine F ^a,b,c   Durham, J Scott ^a,c   Brasher, Penelope M ^a,c   Anderson, Donald W ^a,c   Berean, Kenneth W ^c   MacAulay, Calum E ^b   Lee, J Jack ^d   Rosin, Miriam P ^b,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; CANCER RECURRENCE; CANCER RESEARCH; CARCINOMA IN SITU; DYSPLASIA; FLUORESCENCE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MOUTH CANCER; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; SURGICAL APPROACH; WHITE LIGHT; CLINICAL TRIAL; COMPUTER ASSISTED SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; ECONOMICS; HEAD AND NECK TUMOR; METHODOLOGY; MOUTH TUMOR; MULTICENTER STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

CANADA; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FLUORESCENCE; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; QUALITY-ADJUSTED LIFE YEARS; SURGERY, COMPUTER-ASSISTED;

EID: 80054872933     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-462     Document Type: Article

References (21)

1. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 Version 2.0 2004, Lyon, France: IARCPress.
2. Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, Rajan B. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005, 365(9475):1927-1933. 10.1016/S0140-6736(05)66658-5, 15936419.
3. Mariotto AB, Rowland JH, Ries LAG, Scoppa S, EJ F. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007, 16:566-571. 10.1158/1055-9965.EPI-06-0782, 17372253.
4. Dhooge IJ, De Vos M, Van Cauwenberge PB. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998, 108(2):250-256. 10.1097/00005537-199802000-00017, 9473077.
5. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003, 63(8):1727-1730.
6. van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, Snow GB, Brankenhoff RH. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 2004, 10:3614-3620. 10.1158/1078-0432.CCR-03-0631, 15173067.
7. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 2004, 10(11):3607-3613. 10.1158/1078-0432.CCR-03-0632, 15173066.
8. Tsui IF, Garnis C, Poh CF. A dynamic oral cancer field: unraveling the underlying biology and its clinical implication. Am J Surg Pathol 2009, 33(11):1732-1738. 10.1097/PAS.0b013e3181b669c2, 2885153, 19858864.
9. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994, 73(1):187-190. 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO;2-J, 8275423.
10. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995, 332(7):429-435. 10.1056/NEJM199502163320704, 7619114.
11. Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ, Snow GB, Leemans CR, Braakhuis BJ. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 2001, 7(6):1523-1532.
12. Poh CF, Zhang L, Anderson DW, Durham JS, Williams PM, Priddy RW, Berean KW, Ng S, Tseng OL, MacAulay C, et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res 2006, 12(22):6716-6722. 10.1158/1078-0432.CCR-06-1317, 17121891.
13. Poh CF, Ng SP, Williams PM, Zhang L, Laronde DM, Lane P, Macaulay C, Rosin MP. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple hand-held device. Head Neck 2007, 29(1):71-76. 10.1002/hed.20468, 16983693.
14. Poh CF, MacAulay CE, Zhang L, Rosin MP. Tracing the "at-risk" oral mucosa field with autofluorescence: steps toward clinical impact. Cancer Prev Res (Phila Pa) 2009, 2(5):401-404.
15. EuroQol - Home. , http://www.euroqol.org
16. Shaw JW, Johnson JA, Coons SJ. US Validation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model. Medical Care 2005, 43(3):203-220. 10.1097/00005650-200503000-00003, 15725977.
17. Facit Classification Overview. , http://facitorg000.web108.discountasp.net/qview/class_overview.aspx
18. List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E. The Performance Status Scale for head and neck cancer patients and the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) scale: A study of utility and validity. Cancer 1996, 77:2294-2301. 10.1002/(SICI)1097-0142(19960601)77:11<2294::AID-CNCR17>3.0.CO;2-S, 8635098.
19. Rinkel RN, Verdonk-de Leeuw IM, van Reij EJ, Aaronson NK, Leemans CR. Speech Handicap Index in Patients with Oral and Pharyngeal Cancer: Better Understanding of Patients' Complaints. Head & Neck 2008, 30:868-874. 10.1002/hed.20795, 3200329, 22039475.
20. Pocock SJ, Simon R. Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial. Biometrics 1975, 31:103-115. 10.2307/2529712, 1100130.
21. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000, 6(2):357-362.